Compare CRIS & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRIS | PIII |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | 360 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 10.0M |
| IPO Year | 2000 | N/A |
| Metric | CRIS | PIII |
|---|---|---|
| Price | $0.76 | $2.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $16.67 | $16.25 |
| AVG Volume (30 Days) | ★ 119.7K | 100.9K |
| Earning Date | 03-19-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $32.24 | N/A |
| Revenue Next Year | $66.94 | $14.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.75 | $0.15 |
| 52 Week High | $3.13 | $11.30 |
| Indicator | CRIS | PIII |
|---|---|---|
| Relative Strength Index (RSI) | 28.46 | 52.47 |
| Support Level | N/A | $1.52 |
| Resistance Level | $1.04 | $2.85 |
| Average True Range (ATR) | 0.08 | 0.53 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 1.39 | 30.81 |
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.